The Perinatal Quality Foundation and the American College of Medical Genetics and Genomics, in association with the American College of Obstetricians and Gynecologists, the Society for Maternal-Fetal Medicine, and the National Society of Genetic Counselors, have collaborated to provide education for clinicians and laboratories regarding the use of expanded genetic carrier screening in reproductive medicine. This statement does not replace current screening guidelines, which are published by individual organizations to direct the practice of their constituents. As organizations develop practice guidelines for expanded carrier screening, further direction is likely. The current statement demonstrates an approach for health care providers and laboratories who wish to or who are currently offering expanded carrier screening to their patients. C arrier screening for inherited genetic conditions is an important component of preconception and prenatal care. The purpose of carrier screening is to identify couples at risk for passing on genetic conditions to their offspring. Condition-directed carrier screening has focused most often on the assessment of ancestry and on individual conditions. Limitations to this approach include inaccurate knowledge of ancestry in our increasingly multiethnic society, recognition that genetic conditions do not occur solely in specific ethnic groups, and that screening for individual conditions limits the amount of accessible genetic information for participants.
Today, high-throughput genotyping and sequencing approaches allow for efficient screening of a large number of conditions simultaneously. Use of this technology provides information regarding many more conditions than the currently recommended screening guidelines and is referred to as expanded carrier screening. Although expanded carrier screening provides more comprehensive screening, this method also presents challenges in patient management. Traditional methods of carrier screening generally have focused on conditions that significantly affect quality of life as a result of cognitive or physical disabilities or a requirement for lifelong medical therapies and have a fetal, neonatal, or early childhood onset and well-defined phenotype. In contrast, current expanded panels include additional conditions that have significant variation in their presentation, including variable age of onset. Although some genetic variants on expanded panels have a relatively consistent phenotype, others are less clearly defined (Appendix 1). Expanded carrier screening panels often include conditions for which carrier screening of the general population is not recommended by current practice guidelines (eg, fragile X syndrome, hemochromatosis, and factor V Leiden). [1] [2] [3] Finally, expanded carrier screening panels may include rare conditions; for such disorders, the precise carrier frequency as well as the proportion of condition-causing variants that can be detected may be unknown. Therefore, calculation of residual risk after a negative screening test may not be possible for all conditions. Whether the practitioner follows current professional society recommendations or uses expanded carrier screening, the goal of preconception and prenatal carrier screening is to provide couples with information to optimize pregnancy outcomes based on their personal values and preferences. Carrier identification allows for preconception planning as well as the option of prenatal diagnosis for the couple at risk. Early identification of affected pregnancies allows condition-specific counseling and care.
PROFESSIONAL ORGANIZATION SCREENING GUIDELINES
Professional practice guidelines currently recommend offering carrier screening for individual conditions based on condition severity, race or ethnicity, prevalence, carrier frequency, detection rates, and residual risk. At present, the American College of Obstetricians and Gynecologists, American College of Medical Genetics and Genomics, and National Society of Genetic Counselors recommend panethnic screening for cystic fibrosis, and the American College of Medical Genetics and Genomics recommends panethnic screening for spinal muscular atrophy. Screening recommendations for other conditions are race-or ethnicity-based. Current guidelines are summarized in Table 1 . Unauthorized reproduction of this article is prohibited.
THE EXPANDED SCREENING PARADIGM
b. Tay-Sachs disease carrier testing has a low detection rate in non-Ashkenazi populations using molecular testing for the three common Ashkenazi mutations. Currently, hexosaminidase A enzyme analysis on blood is the best method to identify carriers in all ethnicities.
OFFERING EXPANDED CARRIER SCREENING
When offering expanded carrier screening, the following are appropriate considerations: women of reproductive age should ideally be offered carrier screening before conception. Gamete donors should undergo carrier screening before their use as part of all screening programs. Preconception screening may be offered sequentially; one partner can be screened and, if they screen positive for any condition, the other partner would be offered screening for that condition. Preconception concurrent screening of the couple may also be offered. In pregnancy, decisions regarding sequential compared with concurrent screening may depend on gestational age, availability of the partner, local program structure, and patient preferences. Concurrent screening optimizes time to consider diagnostic testing and reproductive options.
For patients with a positive family history of a genetic condition, genetic counseling is indicated for accurate risk assessment, to review familial variants (if known), and to ensure the most specific carrier test is offered to address the familial risk. Expanded carrier screening does not replace genetic counseling or assessment of familial risk. For couples identified with a risk of an inherited condition, diagnostic testing may be indicated.
Patients and health care providers may be confused regarding the differences between newborn screening and expanded carrier screening. Patients should be aware that newborn screening is mandated by all states and can identify some genetic conditions in the newborn. However, newborn screening may include a different panel of conditions than expanded carrier screening. Newborn screening does not usually detect children who are carriers for the conditions being screened so will not necessarily identify carrier parents at increased risk. Conversely, expanded carrier screening in the preconception or prenatal period is not a substitute for newborn screening and should not be used as a rationale for refusing or not offering newborn screening.
COMPONENTS OF CONSENT FOR EXPANDED CARRIER SCREENING
Individuals offered expanded carrier screening should be provided counseling leading to informed consent or the option to decline and either should be documented in the medical record. Components of consent should include: 
POSTTEST COUNSELING
Health care providers who use expanded carrier screening should have a plan to provide accurate information to patients identified as carriers of a condition. When a pregnant patient is found to be a carrier of an autosomal-recessive condition, the biologic father of the fetus should be offered screening for that condition as soon as possible if concurrent screening was not performed. If one partner is found to be a carrier of an autosomal-recessive condition and the other has a negative screening result for that condition, the chance that the couple will have an affected pregnancy is significantly reduced and no further testing of the partner should be offered; prenatal diagnosis is not indicated. Counseling should include that the partner is unlikely to have a mutation for the same disorder, but a residual risk persists for the couple to have an affected child. An exception is TaySachs disease: if one partner is a carrier and their nonAshkenazi partner is a noncarrier by only molecular testing, further screening through enzyme analysis is strongly recommended. Further risk reduction through sequencing of the gene in question is possible, but this is not routinely recommended and is used only with caution. Uncertainties may be encountered such as a variant of uncertain significance or a novel or less well-described mutation, both of which preclude prediction of the phenotype in compound heterozygotes.
If both partners are identified as carriers of the same autosomal-recessive condition, they have a 25% risk of having an affected child with each pregnancy. Genetic counseling by a certified genetics professional is indicated and for pregnant patients, prenatal diagnosis should be offered.
If an affected fetus is identified, all reproductive options should be discussed including: prenatal management, delivery planning and coordination of care for the child as well as pregnancy termination or adoption planning. In the preconception period, counseling should also review preimplantation genetic diagnosis and use of noncarrier donor gametes as additional options.
Carrier screening results should be available to the patient, and counseling should include an explanation of the condition and its inheritance. Posttest counseling should also include the significance of this information for other family members who may also be carriers (eg, parents or siblings). Written information for the patient to share with relatives about the availability of carrier screening should be available.
CONDITIONS INCLUDED ON PRECONCEPTION AND PRENATAL EXPANDED CARRIER SCREENING PANELS
Expanded panels screen for conditions with a wide range of severity and age of onset and frequently have carrier frequencies that are not known for all populations. The following considerations should be addressed when health care providers select a preconception or prenatal carrier panel for use in practice and as laboratories consider inclusion and exclusion of conditions:
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INTERPRETATION OF MOLECULAR FINDINGS
Expanded carrier screening can be performed by genotyping or by DNA sequencing. Genotyping searches for known pathogenic and likely pathogenic variants. Sequencing analyzes the entire coding region of the gene and identifies alterations from the expected normal sequence. Although genotyping includes only selected variants, sequencing has the potential to identify not only pathogenic and likely pathogenic variants, but also benign and likely benign variants. Sequencing also can identify variants of uncertain significance, which have an uncertain effect on gene function and thus an uncertain relationship to clinical phenotype. Health care providers should also be aware that multiple genes can cause a specific condition and that expanded carrier screening may therefore investigate more than one gene implicated in the pathogenesis of a condition. Also, within any gene, a large number of variants may be investigated. Given these complexities, it is recommended that laboratories include genetic conditions in their testing panels that meet the criteria subsequently. Health care providers are cautioned against routinely offering tests that do not meet these criteria:
1. 
Development of a Curated Data Repository of Variants and Associated Phenotypes
As panethnic genotyping and sequencing is performed on the general population, previously unreported and relatively rare variants will be identified.
To improve the predictive value of carrier testing, these variants and the full phenotypes of homozygotes and compound heterozygotes should be collected and available to clinicians, counselors, and investigators. Similarly, determining the frequency of variants in previously untested ethnic and racial groups is required because risks associated with gene variants may vary with different genetic backgrounds and in different environmental situations. Laboratories share responsibility for collaborative analysis of expanded carrier screening to further our understanding of human mutation.
Education of Physicians and Other Health Care Providers
Obstetricians, reproductive endocrinologists, general practitioners, midwives, nurse practitioners, and other clinical providers will offer most carrier screening. Expanded carrier screening technology offers an opportunity to educate care providers regarding high-throughput genomic technologies, including the risks and benefits of the implementation of these technologies into clinical practice.
Education of Patients
Research is needed to identify best practices to educate individuals about the concept of expanded carrier screening and allow them to make informed decisions. Information needs regarding expanded carrier screening will vary between individuals.
Minimum criteria for what information should be disclosed before screening should be developed and empirically tested to assess patient satisfaction.
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Educational Resources for Health Care Providers and Patients
Educational materials will need to be developed in print, video, or web-based formats that describe the nature and limitations of expanded carrier screening. These materials should be independent of commercial laboratories' marketing materials.
Evaluation of Patient and Health Care Provider Attitudes Toward Expanded Carrier Screening
There remain a number of unsettled issues concerning expanded carrier screening, including the range of severity of the conditions that should be included on panels and whether they should include adult-onset conditions. Specific guidance on these issues will require additional research about patient and health care provider attitudes. 17 
Cost of Expanded Carrier Screening
Future studies that explore the overall cost of implementation of expanded carrier screening are needed. The downstream costs of genetic counseling, partner testing, patient anxiety, and the potential need for prenatal diagnosis need to be considered.
SUMMARY
In this document, representatives from several professional organizations, each with an interest in the implementation of screening for heritable conditions, have collaborated to provide points to consider for clinical providers and laboratories. These are not meant to replace existing practice guidelines and policy statements. Rather, they offer an opportunity for health care providers to better understand expanded carrier screening. Many more conditions, genes, and variants are analyzed when expanded carrier screening is used compared with current screening approaches. As such, expanded carrier screening can provide information about carrier status beyond population estimates and eliminates the need for ethnicity-based screening. However, this approach introduces complexities that require special consideration. Health care providers are reminded that the focus of carrier screening is to identify the at-risk fetus. In some circumstances, molecular testing is not the optimal or currently recommended screening approach (eg, hemoglobinopathies, Tay-Sachs disease, hereditary hemochromatosis). Health care providers are urged to increase their knowledge of genetic screening terminology and remember that residual risk is always present, although not always quantifiable. There are unique research opportunities that are important to pursue to further our understanding of the full effect of expanded carrier screening on patients, health care providers, counselors, laboratories, and a health care system that has a vested interest in reproductive outcomes.
